Foundayo vs Wegovy: Daily Pill vs Weekly Injection

Two GLP-1 receptor agonists, two very different drugs. Foundayo (orforglipron) is Eli Lilly's once-daily oral pill, FDA-approved April 1, 2026. Wegovy (semaglutide) is Novo Nordisk's once-weekly injection, FDA-approved since 2021. They activate the same receptor and produce similar weight loss, but the route, the cost, and the day-to-day experience differ sharply.

Quick Comparison Table

Mechanism: Same Target, Different Chemistry

Both drugs activate the GLP-1 receptor, the molecular switch that controls appetite, gastric emptying, and insulin secretion. The chemistry is what differs. Wegovy is semaglutide, a peptide engineered from native GLP-1 with modifications that extend its half-life to about a week. Foundayo is orforglipron, a non-peptide small molecule discovered through high-throughput screening. Different compounds, same receptor.

That chemistry difference drives every other downstream comparison. Peptides are large, fragile, and degrade in the gut, which is why semaglutide must be injected (or, in Rybelsus, paired with an absorption enhancer that demands fasting). Small molecules survive digestion intact, which is why Foundayo can be a simple daily pill with no special instructions. Both molecules bind the GLP-1 receptor, but they reach it via completely different routes.

Efficacy: Wegovy Wins on Weight Loss, Slightly

The trial evidence is consistent: semaglutide outperforms orforglipron on mean weight loss, but not by a huge margin. STEP-1 produced 14.9% mean weight loss for Wegovy 2.4 mg over 68 weeks. ATTAIN-1 produced 12.4% mean weight loss for Foundayo 36 mg over 72 weeks. Different trial populations, different durations, but the gap is real and reproducible across secondary endpoints.

Where Wegovy pulls further ahead is at the high doses. Wegovy HD at 7.2 mg weekly produces 20.7% mean weight loss in STEP UP. Foundayo's 36 mg dose is the highest tested in Phase 3, and there's no clear path to a higher-dose orforglipron formulation in the near term. If your weight loss target is 15%+, Wegovy and Wegovy HD have the data; Foundayo doesn't.

For glycemic control in patients with concurrent type 2 diabetes, the picture is more nuanced. Semaglutide (as Ozempic) has years of A1C reduction data; orforglipron's ACHIEVE program in diabetic patients showed similar A1C reductions to semaglutide. The diabetes label for Foundayo is expected later in 2026.

Cost: Foundayo Is Roughly One-Third the Price

List prices: Foundayo $499/month, Wegovy $1,349/month. Both have $25/month savings cards for eligible commercially insured patients, so for many patients with good insurance the actual out-of-pocket cost is identical. The list price gap matters most for cash-pay patients, those with high-deductible plans, and self-funded employer plans evaluating coverage decisions.

Novo Nordisk has been responding to GLP-1 price pressure through NovoCare, its direct-to-consumer pharmacy that sells Wegovy at roughly $499/month for the lower starting doses (escalating to higher prices for the maintenance dose). Lilly already runs LillyDirect for Zepbound at similar levels and has extended it to Foundayo. The pricing convergence is real but Foundayo still has a clear list-price advantage.

For more cost analysis, see Wegovy cost, Wegovy without insurance, and Wegovy cost with insurance.

Convenience: Foundayo Wins Decisively

Daily pill versus weekly injection is the headline difference, but the convenience gap goes deeper. Foundayo:

• Taken any time of day, with or without food, with or without water
• No needles, no injection technique to learn, no sharps disposal
• Room-temperature stable, no refrigeration
• Travels easily, no special handling for international flights
• No injection site reactions or rotation routines

Wegovy:

• Once-weekly injection, typically same day each week
• Requires injection technique, alcohol swabs, sharps container
• Pen must be refrigerated until first use, then OK at room temperature 28 days
• Travel logistics with refrigerated medication can be complex
• Injection site reactions in 5-10% of patients; rotation between thigh, abdomen, upper arm

For patients with needle phobia (a real clinical condition affecting 10-20% of adults to varying degrees), Foundayo isn't just more convenient, it's the only viable GLP-1. See Wegovy pen instructions and Wegovy injection sites for what the alternative entails.

Side Effects: Similar Class, Different Patterns

Both drugs cause GI side effects: nausea, vomiting, diarrhea, constipation, abdominal pain. Rates are similar (roughly 30-40% for nausea during titration, falling to 10-15% at maintenance). The pattern differs because of dosing frequency.

Wegovy produces a peak blood level after each weekly injection, then trough levels by day 6-7. Patients often report nausea concentrated in the 24-48 hours after injection, then a clearer few days. Foundayo's daily dosing produces flatter blood levels, which may mean milder peak nausea but more consistent low-level GI symptoms.

Both carry the GLP-1 class boxed warning for medullary thyroid carcinoma based on rodent studies, plus warnings for pancreatitis, gallbladder disease, and severe GI events. Both have hair loss as a known side effect, generally mild and reversible. See Wegovy side effects for the full list and Wegovy nausea management strategies that translate to Foundayo.

Cardiovascular Outcomes: Wegovy Has Real Data

Wegovy has the SELECT trial, which showed semaglutide reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by about 20% in adults with overweight or obesity and established cardiovascular disease. That data led to an expanded FDA label for cardiovascular risk reduction in 2024.

Foundayo does not yet have cardiovascular outcomes data. A Phase 3 cardiovascular outcomes trial is enrolling. For patients with known cardiovascular disease who would benefit from MACE risk reduction as a secondary goal, Wegovy currently has the data and the label. Foundayo may catch up over time, but today this is a clear Wegovy advantage.

Who Should Choose Foundayo

• You have needle phobia or strong injection aversion
• You travel frequently, especially internationally
• You're paying cash and need the lower list price
• You want a daily routine over a weekly ritual
• Your weight loss target is in the 10-15% range, not maximal
• You don't have established cardiovascular disease (so MACE reduction isn't a primary goal)

Who Should Choose Wegovy

• You want maximum weight loss with proven 15%+ mean efficacy (or 20%+ on Wegovy HD)
• You have established cardiovascular disease and want MACE reduction
• You prefer once-weekly dosing over daily pills
• Your insurance covers Wegovy with a low copay
• You're comfortable with self-injection technique

Switching Between the Two

Switching from Wegovy to Foundayo: discontinue Wegovy, start Foundayo at 3 mg daily, titrate per the standard schedule. Some prescribers will skip the 3 mg and 6 mg steps if you tolerated Wegovy 2.4 mg, starting Foundayo at 12 mg. Expect a 2-4 week transition period as orforglipron blood levels build.

Switching from Foundayo to Wegovy: discontinue Foundayo, start Wegovy at 0.25 mg weekly, titrate per the standard 16-week schedule. The full Wegovy titration is recommended even if you tolerated Foundayo 36 mg, because semaglutide's peak-trough pharmacokinetics produce different GI tolerability than orforglipron's flat daily dosing.

Bottom Line

Wegovy produces somewhat more weight loss and has cardiovascular outcomes data. Foundayo is a daily pill, costs a third as much, and avoids needles entirely. For patients optimizing for maximum weight loss or with established cardiovascular disease, Wegovy is still the better choice. For patients optimizing for convenience, cost, or needle avoidance, Foundayo is now a serious first-line option. The presence of both means GLP-1 therapy is finally accessible to patients who previously declined it because of injection aversion or cost.

For more head-to-head comparisons, see Foundayo vs Zepbound, Wegovy vs Zepbound, Wegovy pill vs injection, and the full GLP-1 medications guide.